These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
413 related articles for article (PubMed ID: 22172720)
1. β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Damsky WE; Curley DP; Santhanakrishnan M; Rosenbaum LE; Platt JT; Gould Rothberg BE; Taketo MM; Dankort D; Rimm DL; McMahon M; Bosenberg M Cancer Cell; 2011 Dec; 20(6):741-54. PubMed ID: 22172720 [TBL] [Abstract][Full Text] [Related]
2. Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of Braf(V600E)::Pten(-/-) melanoma. Scortegagna M; Ruller C; Feng Y; Lazova R; Kluger H; Li JL; De SK; Rickert R; Pellecchia M; Bosenberg M; Ronai ZA Oncogene; 2014 Aug; 33(34):4330-9. PubMed ID: 24037523 [TBL] [Abstract][Full Text] [Related]
3. Abl kinase regulation by BRAF/ERK and cooperation with Akt in melanoma. Jain A; Tripathi R; Turpin CP; Wang C; Plattner R Oncogene; 2017 Aug; 36(32):4585-4596. PubMed ID: 28368422 [TBL] [Abstract][Full Text] [Related]
4. Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma. Yang H; Kircher DA; Kim KH; Grossmann AH; VanBrocklin MW; Holmen SL; Robinson JP Oncogene; 2017 Jul; 36(27):3842-3851. PubMed ID: 28263969 [TBL] [Abstract][Full Text] [Related]
9. Suppression of MAPK signaling in BRAF-activated PTEN-deficient melanoma by blocking β-catenin signaling in cancer-associated fibroblasts. Zhou L; Yang K; Dunaway S; Abdel-Malek Z; Andl T; Kadekaro AL; Zhang Y Pigment Cell Melanoma Res; 2018 Mar; 31(2):297-307. PubMed ID: 29045061 [TBL] [Abstract][Full Text] [Related]
10. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Gopal YN; Deng W; Woodman SE; Komurov K; Ram P; Smith PD; Davies MA Cancer Res; 2010 Nov; 70(21):8736-47. PubMed ID: 20959481 [TBL] [Abstract][Full Text] [Related]
11. Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Chien AJ; Moore EC; Lonsdorf AS; Kulikauskas RM; Rothberg BG; Berger AJ; Major MB; Hwang ST; Rimm DL; Moon RT Proc Natl Acad Sci U S A; 2009 Jan; 106(4):1193-8. PubMed ID: 19144919 [TBL] [Abstract][Full Text] [Related]
12. Knockout of MDA-9/Syntenin (SDCBP) expression in the microenvironment dampens tumor-supporting inflammation and inhibits melanoma metastasis. Das SK; Guo C; Pradhan AK; Bhoopathi P; Talukdar S; Shen XN; Emdad L; Subler MA; Windle JJ; Sarkar D; Wang XY; Fisher PB Oncotarget; 2016 Jul; 7(30):46848-46861. PubMed ID: 27341128 [TBL] [Abstract][Full Text] [Related]
13. Aryl hydrocarbon receptor/cytochrome P450 1A1 pathway mediates breast cancer stem cells expansion through PTEN inhibition and β-Catenin and Akt activation. Al-Dhfyan A; Alhoshani A; Korashy HM Mol Cancer; 2017 Jan; 16(1):14. PubMed ID: 28103884 [TBL] [Abstract][Full Text] [Related]
14. The Small GTPase ARF6 Activates PI3K in Melanoma to Induce a Prometastatic State. Yoo JH; Brady SW; Acosta-Alvarez L; Rogers A; Peng J; Sorensen LK; Wolff RK; Mleynek T; Shin D; Rich CP; Kircher DA; Bild A; Odelberg SJ; Li DY; Holmen SL; Grossmann AH Cancer Res; 2019 Jun; 79(11):2892-2908. PubMed ID: 31048499 [TBL] [Abstract][Full Text] [Related]